SCHEMBL6844480

SCHEMBL6844480

NC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 19/20 0.79
MAP2K2 P36507 16/20 0.79
RAF1 P04049 1/20 0.64
PDGFRB P09619 1/20 0.64
CSNK2A2 P19784 1/20 0.64
CSNK2B P67870 1/20 0.64
CSNK2A1 P68400 1/20 0.64
CSNK2A3 Q8NEV1 1/20 0.64
AURKC Q9UQB9 1/20 0.64
CAMK2A Q9UQM7 1/20 0.64
PIM1 P11309 1/20 0.50
CAMK2B Q13554 1/20 0.50
BRAF P15056 1/20 0.49
MAPK1 P28482 1/20 0.49
MAP2K5 Q13163 1/20 0.49
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC2 Q92769 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Zapnometinib SCHEMBL30298104 0.88 MAP2K1 (1.00) MAP2K1MAP2K2RAF1PDGFRBCSNK2A2
Zapnometinib SCHEMBL29362260 0.88 MAP2K1 (1.00) MAP2K1MAP2K2RAF1PDGFRBCSNK2A2
Zapnometinib SCHEMBL1488782 0.88 MAP2K1 (1.00) MAP2K1MAP2K2RAF1PDGFRBCSNK2A2
SCHEMBL29425375 0.88 MAP2K1 (1.00) MAP2K1MAP2K2PIM1CAMK2BBRAF
SCHEMBL3762426 0.88 MAP2K1 (1.00) MAP2K1MAP2K2PIM1CAMK2BBRAF
SCHEMBL5396229 0.86 MAP2K1 (0.77) MAP2K1MAP2K2RAF1PDGFRBCSNK2A2
SCHEMBL29781350 0.85 MAP2K1 (0.76) MAP2K1MAP2K2RAF1PDGFRBCSNK2A2
SCHEMBL5677719 0.85 MAP2K1 (0.79) MAP2K1MAP2K2RAF1PDGFRBCSNK2A2
SCHEMBL4856920 0.82 MAP2K1 (0.71) MAP2K1MAP2K2RAF1PDGFRBCSNK2A2
SCHEMBL4861211 0.81 MAP2K1 (0.82) MAP2K1MAP2K2RAF1PDGFRBCSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2150527-B1 ANTHRANILIC ACID DERIVATIVE AS ANTICANCER AGENT AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2011-01-19 EP disclosed
WO-2008114275-A2 ANTHRANILIC ACID DERIVATIVES AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2008-09-25 WO disclosed
US-20040122058-A1 Use of specific compounds particularly kinase inhibitors for treating viral infections AXXIMA PHARMACEUTICALS AG (DE) 2004-06-24 US disclosed